the Image

Clinical Trial Details

If you are a patient or a caregiver and would like to learn more our cancer clinical trials call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials) or email .

Share this:
Brief Title A Safety Study of SGN-LIV1A in Breast Cancer Patients
Official Title A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in Patients With Metastatic Breast Cancer
Principal Investigator Nanda, Rita
Brief Summary This study will examine the safety and tolerability of SGN-LIV1A in patients with metastatic breast cancer. SGN-LIV1A will be given every 3 weeks alone or in combination with trastuzumab.
Gender Female
Ages 18 Years
Enrollment 306
Accepts Healthy Volunteers No
Lead Sponsor Seattle Genetics, Inc.Industry
Study Design
Study Phase Phase 1
Study Type Interventional
Contact Name Andres Forero-Torres, MD
Contact Phone 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials)
Condition Breast Cancer
Detail for Health Professional (on
More clinical trials by this PI